Serving the Society Since 1986
Advanced Search
Volume 28 Issue 1
February 2013
    Citation: Julian Ruiz-Sáenz, Jairo Jaime, Victor Vera. An Inactivated Vaccine from a Field Strain of Bovine Herpesvirus-1 (BoHV-1) has High Antigenic Mass and Induces Strong Efficacy in a Rabbit Model .VIROLOGICA SINICA, 2013, 28(1) : 36-42.  http://dx.doi.org/10.1007/s12250-013-3283-z
    shu

    An Inactivated Vaccine from a Field Strain of Bovine Herpesvirus-1 (BoHV-1) has High Antigenic Mass and Induces Strong Efficacy in a Rabbit Model

    • 1.

      Microbiology and Epidemiology Group, Faculty of Veterinary Medicine and Animal Science, National University of Colombia, Bogotá 11001, Colombia

    • 2.

      Grupo de Investigación CENTAURO, Agrarian Sciences Faculty, Universidad de Antioquia, A.A. 1226, Medellín, Colombia

    • Corresponding author: Julian Ruiz-Sáenz, julianruizsaenz@gmail.com
    • Received Date: 07 September 2012
      Accepted Date: 17 January 2013
      Available online: 01 February 2013

      Fund Project: the División de Investigación Universidad Nacional de Colombia, grants 202010013254the División de Investigación Universidad Nacional de Colombia, grants No.20201007738

    • Bovine Herpesvirus-1 (BoHV-1) is a DNA virus belonging to the family Herpesviridae, subfamily Alfaherpesvirinae; it is a worldwide pathogen, causing serious economic losses in livestock. In Colombia there have been multiple isolates of BoHV-1 that have been subjected to molecular characterization, classifying most of the country isolates as BoHV-1.1. In the present study we developed and evaluated an ethyleneimine binary inactivated isolate from the native BoHV-1 strain (Córdoba-2) in a rabbit model of vaccination and infection. The vaccine was evaluated in two phases, one of immunogenicity with vaccination and a booster after 21 days, and an evaluation phase of protection against challenge with a highly virulent reference strain. The results demonstrate optimum serum-conversion, with protective neutralizing antibody titers 28 days post vaccination and optimal protection against challenge with the reference strain with decreased clinical signs of infection, protection against the onset of fever and decrease of virus excretion post challenge. In conclusion, our results show the enormous potential that an immunogenic inactivated vaccine has produced from the native BoHV-1.1 strain, which produces a high antigen mass to the vaccine to induce optimal immunity and protection, and it is a strong candidate for evaluation and possible future use in different cattle populations.
    • 加载中

      1. Bahnemann H G. 1990. Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine, 8: 299-303.
          doi: 10.1016/0264-410X(90)90083-X

      2. Caron L, Flores E F, Weiblen R, Scherer C F, Irigoyen L F, Roehe P M, Odeon A and Sur J H. 2002. Latent infection by bovine herpesvirus type-5 in experimentally infected rabbits: virus reactivation, shedding and recrudescence of neurological disease. Vet Microbiol, 84: 285-295.
          doi: 10.1016/S0378-1135(01)00441-2

      3. Chung H, Kim T W, Kwon M, Kwon I C and Jeong S Y. 2001. Oil components modulate physical characteristics and function of the natural oil emulsions as drug or gene delivery system. J Control Release, 71: 339-350.
          doi: 10.1016/S0168-3659(00)00363-1

      4. Davison A J, Eberle R, Ehlers B, Hayward G S, McGeoch D J, Minson A C, Pellett P E, Roizman B, Studdert M J and Thiry E. 2009. The order Herpesvirales. Arch Virol, 154: 171-177.
          doi: 10.1007/s00705-008-0278-4

      5. DesCoteaux L, Cecyre D, Elsener J and Beauchamp G. 2003. Comparison of humoral immune responses in dairy heifers vaccinated with 3 different commercial vaccines against bovine viral diarrhea virus and bovine herpesvirus-1. Can Vet J, 44: 816-821.

      6. Duque H, Marshall R L, Israel B A and Letchworth G J. 1989. Effects of formalin inactivation on bovine herpes virus-1 glycoproteins and antibody response elicited by formalin-inactivated vaccines in rabbits. Vaccine, 7: 513-520.
          doi: 10.1016/0264-410X(89)90275-2

      7. Engels M, Steck F and Wyler R. 1981. Comparison of the genomes of infectious bovine rhinotracheitis and infectious pustular vulvovaginitis virus strains by restriction endonuclease analysis. Arch Virol, 67: 169-174.
          doi: 10.1007/BF01318601

      8. Hierholzer J C and Killington R A. 1996. Virus isolation and quantitation, p. 25-46. In Mahy B W J and Kangro H O (ed.), Virology methods manual. Academic Press, London.

      9. Ioannou X P, Griebel P, Hecker R, Babiuk L A and van Drunen Littel-van den Hurk S. 2002. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol, 76: 9002-9010.
          doi: 10.1128/JVI.76.18.9002-9010.2002

      10. Kamaraj G, Rana S K and Srinivasan V A. 2009. Serological response in cattle immunized with inactivated oil and Algel adjuvant vaccines against infectious bovine rhinotracheitis. New Microbiol, 32: 135-141.

      11. Lesko J, Veber P, Hrda M and Feketeova M. 1993. Large-scale production of infectious bovine rhinotracheitis virus in cell culture on microcarriers. Acta Virol, 37: 73-78.

      12. Miller J M, Whetstone C A, Bello L J and Lawrence W C. 1991. Determination of ability of a thymidine kinase-negative deletion mutant of bovine herpesvirus-1 to cause abortion in cattle. Am J Vet Res, 52: 1038-1043.

      13. Muylkens B, Meurens F, Schynts F, Farnir F, Pourchet A, Bardiau M, Gogev S, Thiry J, Cuisenaire A, Vanderplasschen A and Thiry E. 2006. Intraspecific bovine herpesvirus 1 recombinants carrying glycoprotein E deletion as a vaccine marker are virulent in cattle. J Gen Virol, 87: 2149-2154.
          doi: 10.1099/vir.0.81969-0

      14. OIE. 2004. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, 5th ed. OIE, Paris, France.

      15. Parreno V, Lopez M V, Rodriguez D, Vena M M, Izuel M, Filippi J, Romera A, Faverin C, Bellinzoni R, Fernandez F and Marangunich L. 2010. Development and statistical validation of a guinea pig model for vaccine potency testing against Infectious Bovine Rhinothracheitis (IBR) virus. Vaccine, 28: 2539-2549.
          doi: 10.1016/j.vaccine.2010.01.035

      16. Pastoret P P and Thiry E. 1985. Diagnosis and prophylaxis of infectious bovine rhinotracheitis: the role of virus latency. Comp Immunol Microbiol Infect Dis, 8: 35-42.
          doi: 10.1016/0147-9571(85)90052-9

      17. Patel J R. 2004. Evaluation of a quadrivalent inactivated vaccine for the protection of cattle against diseases due to common viral infections. J S Afr Vet Assoc, 75: 137-146.

      18. Patel J R. 2005. Relative efficacy of inactivated bovine herpesvirus-1 (BHV-1) vaccines. Vaccine, 23: 4054-4061.
          doi: 10.1016/j.vaccine.2004.12.010

      19. Peters A R, Thevasagayam S J, Wiseman A and Salt J S. 2004. Duration of immunity of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI3V, BVDV and BRSV in experimentally infected calves. Prev Vet Med, 66: 63-77.
          doi: 10.1016/j.prevetmed.2004.08.001

      20. Rossi C R and Kiesel G K. 1982. Effect of infectious bovine rhinotracheitis virus immunization on viral shedding in challenge-exposed calves treated with dexamethasone. Am J Vet Res, 43: 1576-1579.

      21. Ruiz-Saenz J, Jaime J and Vera V. 2009. Bovine Herpesvirus-1 Vaccine's: A Look From The Past To The Immunization Future. Acta biol Colomb, 14: 3-20.

      22. Ruiz-Saenz J, Jaime J, Ramirez G and Vera V. 2012. Molecular and in vitro characterization of field isolates of bovine herpesvirus-1. Virol Sin, 27: 26-37.
          doi: 10.1007/s12250-012-3221-5

      23. Schudel A A, Carrillo B J, Wyler R and Metzler A E. 1986. Infections of calves with antigenic variants of bovine herpesvirus 1 (BHV-1) and neurological disease. Zentralbl Veterinarmed B, 33: 303-310.

      24. Toussaint J F, Letellier C, Paquet D, Dispas M and Kerkhofs P. 2005. Prime-boost strategies combining DNA and inactivated vaccines confer high immunity and protection in cattle against bovine herpesvirus-1. Vaccine, 23: 5073-5081.
          doi: 10.1016/j.vaccine.2005.06.006

      25. Valera A R, Pidone C L, Massone A R, Quiroga M A, Riganti J G, Corva S G and Galosi C M. 2008. A simple method of infecting rabbits with Bovine herpesvirus 1 and 5. J Virol Methods, 150: 77-79.
          doi: 10.1016/j.jviromet.2008.03.008

      26. Zimmerman A D, Buterbaugh R E, Herbert J M, Hass J M, Frank N E, Luempert Iii L G and Chase C C. 2007. Efficacy of bovine herpesvirus-1 inactivated vaccine against abortion and stillbirth in pregnant heifers. J Am Vet Med Assoc, 231: 1386-1389.
          doi: 10.2460/javma.231.9.1386

    • 加载中

    Figures(5)

    PDF

    Article Metrics

    Article views(4386) PDF downloads(16) Cited by()

    Related
    Proportional views

      An Inactivated Vaccine from a Field Strain of Bovine Herpesvirus-1 (BoHV-1) has High Antigenic Mass and Induces Strong Efficacy in a Rabbit Model

        Corresponding author: Julian Ruiz-Sáenz, julianruizsaenz@gmail.com
      • 1. Microbiology and Epidemiology Group, Faculty of Veterinary Medicine and Animal Science, National University of Colombia, Bogotá 11001, Colombia
      • 2. Grupo de Investigación CENTAURO, Agrarian Sciences Faculty, Universidad de Antioquia, A.A. 1226, Medellín, Colombia
      • Received Date: 07 September 2012
      • Accepted Date: 17 January 2013
      Fund Project:  the División de Investigación Universidad Nacional de Colombia, grants 202010013254the División de Investigación Universidad Nacional de Colombia, grants No.20201007738

      Abstract: Bovine Herpesvirus-1 (BoHV-1) is a DNA virus belonging to the family Herpesviridae, subfamily Alfaherpesvirinae; it is a worldwide pathogen, causing serious economic losses in livestock. In Colombia there have been multiple isolates of BoHV-1 that have been subjected to molecular characterization, classifying most of the country isolates as BoHV-1.1. In the present study we developed and evaluated an ethyleneimine binary inactivated isolate from the native BoHV-1 strain (Córdoba-2) in a rabbit model of vaccination and infection. The vaccine was evaluated in two phases, one of immunogenicity with vaccination and a booster after 21 days, and an evaluation phase of protection against challenge with a highly virulent reference strain. The results demonstrate optimum serum-conversion, with protective neutralizing antibody titers 28 days post vaccination and optimal protection against challenge with the reference strain with decreased clinical signs of infection, protection against the onset of fever and decrease of virus excretion post challenge. In conclusion, our results show the enormous potential that an immunogenic inactivated vaccine has produced from the native BoHV-1.1 strain, which produces a high antigen mass to the vaccine to induce optimal immunity and protection, and it is a strong candidate for evaluation and possible future use in different cattle populations.

        HTML